RxDoctor Payments Data

Frederick Reed, MD

Family Medicine · Davenport, WANPI 1467411157

Payments from drug & device makers

$1,666in general payments, 2019–2025

Across 124 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$395
  • Johnson & Johnson$322
  • Amgen$277
  • Novo Nordisk$223
  • AstraZeneca$166
  • Takeda Pharmaceuticals U.S.A., Inc.$51
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$1,57194%
  • Education$956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,666 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$6,337
Medicare patients
43
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$132,009
XareltoRivaroxaban64$65,100
EliquisApixaban40$37,803
MounjaroTirzepatide26$34,523
JanuviaSitagliptin Phosphate34$30,237
Breo ElliptaFluticasone/Vilanterol49$27,314
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr49$24,141
FarxigaDapagliflozin Propanediol38$22,616
Spiriva HandihalerTiotropium Bromide30$20,029
Nurtec OdtRimegepant Sulfate12$19,336
Tresiba Flextouch U-200Insulin Degludec14$16,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,118
TrulicityDulaglutide13$12,514
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$11,855
Spiriva RespimatTiotropium Bromide14$10,249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$223$132,009124 claims
GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta$15$66,573122 claims
Johnson & JohnsonXarelto$322$65,10064 claims
PfizerEliquis, Nurtec Odt$395$57,13952 claims
Lilly USA, LLCMounjaro, Trulicity$24$47,03739 claims
AstraZenecaFarxiga, Symbicort$166$30,81767 claims
MerckJanuvia$13$30,23734 claims
Boehringer IngelheimSpiriva Respimat, Jardiance$39$17,49126 claims
NovartisEntresto$36$7,85012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Davenport

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →